Cargando…
Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy
Background: Neoadjuvant chemotherapy (NAC) has been of recent interest as an alternative to upfront surgery followed by adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). However, a subset of patients does not respond to NAC and may have been better managed by upfront su...
Autores principales: | Sahni, Sumit, Nahm, Christopher, Krisp, Christoph, Molloy, Mark P., Mehta, Shreya, Maloney, Sarah, Itchins, Malinda, Pavlakis, Nick, Clarke, Stephen, Chan, David, Gill, Anthony J., Howell, Viive M., Samra, Jaswinder, Mittal, Anubhav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064619/ https://www.ncbi.nlm.nih.gov/pubmed/32195182 http://dx.doi.org/10.3389/fonc.2020.00237 |
Ejemplares similares
-
Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis
por: Maloney, Sarah, et al.
Publicado: (2021) -
The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer
por: Nahm, Christopher B., et al.
Publicado: (2022) -
Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2023) -
The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer
por: Maloney, Sarah, et al.
Publicado: (2023) -
The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer
por: Maloney, Sarah, et al.
Publicado: (2023)